Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

BioMed Research International
Volume 2013, Article ID 308130, 12 pages
http://dx.doi.org/10.1155/2013/308130
Research Article

Dual Inhibiting Senescence and Epithelial-to-Mesenchymal Transition by Erythropoietin Preserve Tubular Epithelial Cell Regeneration and Ameliorate Renal Fibrosis in Unilateral Ureteral Obstruction

1Nephrology Unit, Department of Medicine, Faculty of Medicine, Thammasat University (Rangsit Campus), Khlong Nueng, Khlong Luang, Pathum Thani 12121, Thailand
2Division of Biochemistry, Department of Preclinical Sciences, Faculty of Medicine, Thammasat University (Rangsit Campus), Khlong Nueng, Khlong Luang, Pathum Thani 12121, Thailand
3Department of Paediatric, Faculty of Medicine, Thammasat University (Rangsit Campus), Khlong Nueng, Khlong Luang, Pathum Thani 12121, Thailand

Received 17 July 2013; Revised 1 October 2013; Accepted 5 October 2013

Academic Editor: Youhua Liu

Copyright © 2013 Adis Tasanarong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. D. Truong, G. Petrusevska, G. Yang et al., “Cell apoptosis and proliferation in experimental chronic obstructive uropathy,” Kidney International, vol. 50, no. 1, pp. 200–207, 1996. View at Google Scholar · View at Scopus
  2. A. Melk and P. F. Halloran, “Cell senescence and its implications for nephrology,” Journal of the American Society of Nephrology, vol. 12, no. 2, pp. 385–393, 2001. View at Google Scholar · View at Scopus
  3. Y. Liu, “New insights into epithelial-mesenchymal transition in kidney fibrosis,” Journal of the American Society of Nephrology, vol. 21, no. 2, pp. 212–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. T. B. L. Kirkwood and S. N. Austad, “Why do we age?” Nature, vol. 408, no. 6809, pp. 233–238, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Campisi and F. d'Adda Di Fagagna, “Cellular senescence: when bad things happen to good cells,” Nature Reviews Molecular Cell Biology, vol. 8, no. 9, pp. 729–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Matsuura, N. G. Denissova, G. Wang, D. He, J. Long, and F. Liu, “Cyclin-dependent kinases regulate the antiproliferative function of Smads,” Nature, vol. 430, no. 6996, pp. 226–231, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Serrano, G. J. Hannon, and D. Beach, “A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4,” Nature, vol. 366, no. 6456, pp. 704–707, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Vijayachandra, J. Lee, and A. B. Glick, “Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model,” Cancer Research, vol. 63, no. 13, pp. 3447–3452, 2003. View at Google Scholar · View at Scopus
  9. K. Vijayachandra, W. Higgins, J. Lee, and A. Glick, “Induction of p16ink4a and p19ARF by TGFβ1 contributes to growth arrest and senescence response in mouse keratinocytes,” Molecular Carcinogenesis, vol. 48, no. 3, pp. 181–186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. F. Halloran, A. Melk, and C. Barth, “Rethinking chronic allograft nephropathy: the concept of accelerated senescence,” Journal of the American Society of Nephrology, vol. 10, no. 1, pp. 167–181, 1999. View at Google Scholar · View at Scopus
  11. Y. Liu, “Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention,” Journal of the American Society of Nephrology, vol. 15, no. 1, pp. 1–12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Sato, Y. Muragaki, S. Saika, A. B. Roberts, and A. Ooshima, “Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction,” Journal of Clinical Investigation, vol. 112, no. 10, pp. 1486–1494, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Zhang, L. Sun, W. Xian et al., “Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-β/Smad activity,” Laboratory Investigation, vol. 90, no. 3, pp. 436–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Inazaki, Y. Kanamaru, Y. Kojima et al., “Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction,” Kidney International, vol. 66, no. 2, pp. 597–604, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Zeisberg, J. Hanai, H. Sugimoto et al., “BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury,” Nature Medicine, vol. 9, no. 7, pp. 964–968, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Tyler, H. Robertson, T. A. Booth, A. D. Burt, and J. A. Kirby, “Chronic allograft nephropathy: intraepithelial signals generated by transforming growth factor-β and bone morphogenetic protein-7,” The American Journal of Transplantation, vol. 6, no. 6, pp. 1367–1376, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Strutz, H. Okada, C. W. Lo et al., “Identification and characterization of a fibroblast marker: FSP1,” Journal of Cell Biology, vol. 130, no. 2, pp. 393–405, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Iwano, D. Plieth, T. M. Danoff, C. Xue, H. Okada, and E. G. Neilson, “Evidence that fibroblasts derive from epithelium during tissue fibrosis,” Journal of Clinical Investigation, vol. 110, no. 3, pp. 341–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. E. J. Sharples, N. Patel, P. Brown et al., “Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2115–2124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. S. H. Lee, C. Li, S. W. Lim et al., “Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy,” The American Journal of Nephrology, vol. 25, no. 1, pp. 64–76, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. H. Park, M. J. Choi, I. K. Song et al., “Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-β-induced epithelial-to-mesenchymal transition,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1497–1507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Kumral, S. Gonenc, O. Acikgoz et al., “Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats,” Biology of the Neonate, vol. 87, no. 1, pp. 15–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Ribatti, A. Vacca, A. M. Roccaro, E. Crivellato, and M. Presta, “Erythropoietin as an angiogenic factor,” European Journal of Clinical Investigation, vol. 33, no. 10, pp. 891–896, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Aydin, J. Duijs, I. M. Bajema, A. J. van Zonneveld, and T. J. Rabelink, “Erythropoietin, progenitors, and repair,” Kidney International, Supplement, vol. 72, no. 107, pp. S16–S20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kuriyama, H. Tomonari, H. Yoshida, T. Hashimoto, Y. Kawaguchi, and O. Sakai, “Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients,” Nephron, vol. 77, no. 2, pp. 176–185, 1997. View at Google Scholar · View at Scopus
  26. C. Gouva, P. Nikolopoulos, J. P. A. Ioannidis, and K. C. Siamopoulos, “Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial,” Kidney International, vol. 66, no. 2, pp. 753–760, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Melk, B. M. W. Schmidt, O. Takeuchi, B. Sawitzki, D. C. Rayner, and P. F. Halloran, “Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney,” Kidney International, vol. 65, no. 2, pp. 510–520, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Melk, B. M. W. Schmidt, A. Vongwiwatana, D. C. Rayner, and P. F. Halloran, “Increased expression of senescence-associated cell cycle inhibitor p16/INK4a in deteriorating renal transplants and diseased native kidney,” The American Journal of Transplantation, vol. 5, no. 6, pp. 1375–1382, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Sis, A. Tasanarong, F. Khoshjou, F. Dadras, K. Solez, and P. F. Halloran, “Accelerated expression of senescence associated cell cycle inhibitor p16INK4A in kidneys with glomerular disease,” Kidney International, vol. 71, no. 3, pp. 218–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Senturk, M. Mumcuoglu, O. Gursoy-Yuzugullu, B. Cingoz, K. C. Akcali, and M. Ozturk, “Transforming growth factor-β induces senescence in hepatocellular carcinoma cells and inhibits tumor growth,” Hepatology, vol. 52, no. 3, pp. 966–974, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Y. Kua, H. Liu, W. F. Leong et al., “c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression,” Nature Cell Biology, vol. 14, no. 7, pp. 727–737, 2012. View at Publisher · View at Google Scholar
  32. S. R. Patel and G. R. Dressler, “BMP7 signaling in renal development and disease,” Trends in Molecular Medicine, vol. 11, no. 11, pp. 512–518, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Guarino, A. Tosoni, and M. Nebuloni, “Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition,” Human Pathology, vol. 40, no. 10, pp. 1365–1376, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Y. Lan and A. C. Chung, “TGF-β/Smad signaling in kidney disease,” Seminars in Nephrology, vol. 32, no. 3, pp. 236–243, 2012. View at Publisher · View at Google Scholar
  35. M. D. Sanchez-Nio, A. Benito-Martin, S. Gonalves et al., “TNF superfamily: a growing saga of kidney injury modulators,” Mediators of Inflammation, vol. 2010, Article ID 182958, 11 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. D. V. Barreto, F. C. Barreto, S. Liabeuf et al., “Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease,” Kidney International, vol. 77, no. 6, pp. 550–556, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Liu, J. R. Yang, Y. N. He et al., “Accelerated senescence of renal tubular epithelial cells is associated with disease progression of patients with immunoglobulin A, (IgA) nephropathy,” Translational Research, vol. 159, no. 6, pp. 454–463, 2012. View at Publisher · View at Google Scholar
  38. H. Braun, B. M. Schmidt, M. Raiss et al., “Cellular senescence limits regenerative capacity and allograft survival,” Journal of the American Society of Nephrology, vol. 23, no. 9, pp. 1467–1473, 2012. View at Publisher · View at Google Scholar
  39. F. Liu and I. Matsuura, “Inhibition of Smad antiproliferative function by CDK phosphorylation,” Cell Cycle, vol. 4, no. 1, pp. 63–66, 2005. View at Google Scholar · View at Scopus
  40. K. Kitada, D. Nakano, H. Hitomi et al., “Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor-α in human proximal tubular cells,” Clinical and Experimental Pharmacology and Physiology, vol. 39, no. 10, pp. 858–863, 2012. View at Publisher · View at Google Scholar
  41. T. Bihani, D. X. Mason, T. J. Jackson, S. C. Chen, B. Boeltner, and A. W. Lin, “Differential oncogenic ras signaling and senescence in tumor cells,” Cell Cycle, vol. 3, no. 9, pp. 1201–1207, 2004. View at Google Scholar · View at Scopus
  42. F. H. Bahlmann, R. Song, S. M. Boehm et al., “Low-dose therapy with the long-acting erythropoietin analogue darbepoetin α persistently activates endothelial Akt and attenuates progressive organ failure,” Circulation, vol. 110, no. 8, pp. 1006–1012, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Cassis, L. Gallon, A. Benigni et al., “Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury,” Kidney International, vol. 81, no. 9, pp. 903–918, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Srisawat, K. Manotham, S. Eiam-Ong, P. Katavetin, K. Praditpornsilpa, and S. Eiam-Ong, “Erythropoietin and its non-erythropoietic derivative: do they ameliorate renal tubulointerstitial injury in ureteral obstruction?” International Journal of Urology, vol. 15, no. 11, pp. 1011–1017, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. K. Chang, D. E. Choi, K. R. Na et al., “Erythropoietin attenuates renal injury in an experimental model of rat unilateral ureteral obstruction via anti-inflammatory and anti-apoptotic effects,” Journal of Urology, vol. 181, no. 3, pp. 1434–1443, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Y. Lan, “Diverse roles of TGF-β/Smads in renal fibrosis and inflammation,” International Journal of Biological Sciences, vol. 7, no. 7, pp. 1056–1067, 2011. View at Google Scholar
  47. S. B. Krantz, “Erythropoietin,” Blood, vol. 77, no. 3, pp. 419–434, 1991. View at Google Scholar · View at Scopus
  48. C. Westenfelder, D. L. Biddle, and R. L. Baranowski, “Human, rat, and mouse kidney cells express functional erythropoietin receptors,” Kidney International, vol. 55, no. 3, pp. 808–820, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Brines, G. Grasso, F. Fiordaliso et al., “Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 41, pp. 14907–14912, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Brines and A. Cerami, “Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise,” Kidney International, vol. 70, no. 2, pp. 246–250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. K. H. Su, S. K. Shyue, Y. R. Kou et al., “β common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase,” Journal of Cellular Physiology, vol. 226, no. 12, pp. 3330–3339, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. M. Coldewey, A. I. Khan, A. Kapoor et al., “Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor,” Kidney International, vol. 84, no. 3, pp. 482–490, 2013. View at Publisher · View at Google Scholar